GSK touts 2-month HIV data as Cabenuva awaits FDA redemption by Angus Liu Monday, March 9, 2020 Data showed a combo of ViiV's cabotegravir and J&J's rilpivirine given very two months was similarly effective to once-monthly Cabenuva.
GSK's long-acting HIV injectable hits FDA snag by Angus Liu Monday, December 23, 2019 GSK's ViiV said the CRL is related to chemistry manufacturing and controls, not the drug's safety profile.
GSK's ViiV rolls first campaign for new HIV med Dovato by Beth Snyder Bulik Wednesday, October 9, 2019 GlaxoSmithKline’s first campaign for new two-in-one HIV pill Dovato centers on real patients who want to be seen for who they are, not as a diagnosis.
ViiV's award-winning HIV theater show set for New York run by Beth Snyder Bulik Tuesday, September 10, 2019 ViiV Healthcare’s award-winning theatrical performance about the real-life experiences of black gay men living with HIV debuts in New York this week.
New respiratory drugs, Shingrix help GSK weather Advair generics by Angus Liu Wednesday, July 24, 2019 GKS's respiratory franchise holds its ground amid Advair generic attack, as its oncology business takes shape.
ViiV builds confidence in 2-drug HIV pill with new Dovato data by Angus Liu Wednesday, July 24, 2019 Dovato keeps working in previously untreated patients for at least two years, and it matches three-drug combos in virally suppressed adults.
Aiming for Gilead’s HIV lead, GSK touts Dovato switching data by Angus Liu Wednesday, July 10, 2019 At least based on recent IQVIA data, analysts suspect that Dovato will be of threat to Gilead any time soon.
GSK tweaks rep compensation rules to recruit and retain talent by Beth Snyder Bulik Thursday, May 23, 2019 GSK has the strictest sales pay rules in the industry, but it's loosening up. It will now allow specialty salespeople to take home bigger paychecks.
GSK's Shingrix skyrockets toward the £1B mark by Angus Liu Wednesday, May 1, 2019 GSK's shingles vaccine Shingrix trounced expectations, but its HIV franchise is suffering on new competition from Gilead.
HIV drugmakers ViiV, Gilead top pharma reputation survey by Beth Snyder Bulik Thursday, April 18, 2019 Pharma’s reputation is holding steady with patient groups with an annual study finding 41% giving pharma good marks, similar to 43% the year before.
